It all depends on how you look at things. According to new data, the number of new drugs approved by FDA in 2008 rose and was the highest it's been in three years. Not so fast, says blogger Merrill Goozner, who argues that numbers don't reflect what is really an ongoing "innovation drought" in the pharma pipeline.
Alas, let's do some looking ahead. Eye on FDA has a nice preview of what's in store on the regulatory front for the upcoming year.
And worried about that 401K filled with company stock? Take heart in that Wall Street analysts are predicting that stock prices for most Big Pharma companies have nowhere to go but up. (Have we heard this before?)
--PWT
